|
Press Releases |
|
|
|
Thursday, September 17, 2020 |
|
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development |
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s). more info >> |
|
Dyadic宣布與江蘇恆瑞醫藥合作開發生物藥物 |
全球生物技術公司Dyadic 國際股份有限公司(以下簡稱“ Dyadic”或“公司”)(納斯達克股票代碼:DYAI)一直致力於改進和應用其專有的C1基因表達平台,加速生物疫苗、藥物和其他生物製品的開發、降低生產成本並改善其性能,具有靈活的商業規模。今天宣布與江蘇恆瑞醫藥有限公司(“恆瑞”)(SSE:600276)合作,將Dyadic的C1技術應用於選定的恆瑞生物藥物的開發中。 more info >> |
|
Dyadic宣布与江苏恒瑞医药合作开发生物药物 |
全球生物技术公司Dyadic 国际股份有限公司(以下简称“ Dyadic”或“公司”)(纳斯达克股票代码:DYAI)一直致力于改进和应用其专有的C1基因表达平台,加速生物疫苗、药物和其他生物制品的开发、降低生产成本并改善其性能,具有灵活的商业规模。今天宣布与江苏恒瑞医药有限公司(“恒瑞”)(SSE:600276)合作,将Dyadic的C1技术应用于选定的恒瑞生物药物的开发中。 more info >> |
|
Tuesday, March 31, 2020 |
|
Dyadic宣布與藥明生物達成非排他性研究許可協議 |
全球生物技術公司Dyadic國際股份有限公司(以下簡稱“ Dyadic”或“公司”)(納斯達克股票代碼:DYAI)一直致力於改進和應用其專有的C1基因表達平台,加速生物疫苗、藥物和其他生物製品的開發、降低生產成本並改善其性能,具有靈活的商業規模。公司今天宣布,它已與全球領先的開放式生物製品技術平台公司及醫藥合同定制研發生產企業(CDMO)——藥明生物攜手,共同進行非排他性研究合作。 more info >> |
|
Dyadic宣布与药明生物达成非排他性研究许可协议 |
全球生物技术公司Dyadic国际股份有限公司(以下简称“ Dyadic”或“公司”)(纳斯达克股票代码:DYAI)一直致力于改进和应用其专有的C1基因表达平台,加速生物疫苗、药物和其他生物制品的开发、降低生产成本并改善其性能,具有灵活的商业规模。公司今天宣布,它已与全球领先的开放式生物制品技术平台公司及医药合同定制研发生产企业(CDMO)——药明生物携手,共同进行非排他性研究合作。 more info >> |
|
Monday, March 30, 2020 |
|
Dyadic Announces Nonexclusive Research License with WuXi Biologics |
Dyadic International, Inc. (NASDAQ:DYAI) today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Contract Development and Manufacturing Organization. more info >> |
|
Thursday, May 9, 2019 |
|
Dyadic攜手印度血清研究所 Serum研發和製造 全球廣泛使用且可負擔得起的抗體產品和疫苗 |
Dyadic國際股份有限公司(以下簡稱''Dyadic'')(納斯達克:DYAI)專注於深入改善和應用旗下專利級C1基因表達平台來加速生物疫苗、藥物和其他生物產品的開發進程,降低生產成本,改善效用,推動靈活的商用普及。 more info >> |
|
Dyadic携手印度血清研究所 Serum研发和制造 全球广泛使用且可负担得起的抗体产品和疫苗 |
Dyadic国际股份有限公司(以下简称''Dyadic'')(纳斯达克:DYAI)专注于深入改善和应用旗下 专利级C1基因表达平台来加速生物疫苗、药物和其他生物产品的开发进程,降低生产成本,改善效用,推动灵活的商用普及。 more info >> |
|
Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines |
Dyadic International, Inc. is pleased to announce a research and commercialization collaboration with Serum Institute of India Pvt., Ltd, one of the world's largest vaccine manufacturers, to develop and manufacture up to twelve antibodies and vaccines using Dyadic's C1 gene expression platform. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
富士通など、モダナイゼーションに特化したファイナンスサービスを提供開始
Dec 23, 2024 10:30: JST
|
|
|
Trio AI Establishes Partnership Ecosystem for Artificial Intelligence Super Computing (AISC)
Dec 23, 2024 09:07 HKT/SGT
|
|
|
Hong Kong Vocational Education Service in Joint Construction of the 'Belt and Road' Vocational Education Symposium
Dec 23, 2024 09:04 HKT/SGT
|
|
|
Summit Group Responds to White Paper Citing Governance Issues in Bangladesh's Power and Energy Sector
Dec 23, 2024 09:00 HKT/SGT
|
|
|
AEON Credit Revenue Up 9.4% to HK$1,304.6 Million for First Nine Months of FY2024/25
Dec 23, 2024 09:00 HKT/SGT
|
|
|
Huatai Securities Achieves MSCI ESG AAA Rating, the Highest Rating among Global Investment Banks
Dec 23, 2024 08:59 HKT/SGT
|
|
|
安眺科技有限公司與亞洲脈絡有限公司合作 革新資料傳輸和網絡解決方案
Dec 23, 2024 08:44 HKT/SGT
|
|
|
TechGALA 2025 - 愛知縣首屆國際初創企業大會
Dec 23, 2024 08:00 HKT/SGT
|
|
|
The finest places to live, work, and thrive in Asia are celebrated at the 19th PropertyGuru Asia Property Awards Grand Final
Dec 23, 2024 07:50 HKT/SGT
|
|
|
Mainland China, Hong Kong, Macau companies triumph at finale of 2024 PropertyGuru Asia Property Awards
Dec 22, 2024 20:50 HKT/SGT
|
|
|
The 2024 PropertyGuru Asia Property Awards International Luncheon celebrates real estate achievements in the Middle East and South Asia
Dec 22, 2024 19:30 HKT/SGT
|
|
|
Virturo Elite Club: Unlock Exclusive Wealth-Building Opportunities for High-Net-Worth Individuals
Dec 21, 2024 09:30: JST
|
|
|
Pathwizz Redefines Trust in Digital Transactions with Award-Winning Support and Verified Platforms 'Wizz Support'
Dec 21, 2024 09:00: JST
|
|
|
Virturo Elite Club: Unlock Exclusive Wealth-Building Opportunities for High-Net-Worth Individuals
Dec 21, 2024 08:00 HKT/SGT
|
|
|
Pathwizz Redefines Trust in Digital Transactions with Award-Winning Support and Verified Platforms 'Wizz Support'
Dec 21, 2024 07:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|